Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression. Patients deemed eligible for Taletrectinib by their physicians were enrolled after providing informed consent. Taletrectinib will be administered according to clinical practice and data on treatment patterns, clinical outcomes, and safety will be collected during routine evaluations.

NCT Number	NCT07199010
Lead Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions	Non-small Lung Cancer
Enrollment	50 participants
Start Date	2025-10
Primary Completion	2027-09 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-30